Erythropoietin and small molecule agonists of the tissue-protective erythropoietin receptor increase FXN expression in neuronal cells in vitro and in Fxn-deficient KIKO mice in vivo

Neuropharmacology
James L MillerJeffrey R Spencer

Abstract

Friedreich's ataxia (FA) is a progressive neurodegenerative disease caused by reduced levels of the mitochondrial protein frataxin (FXN). Recombinant human erythropoietin (rhEPO) increased FXN protein in vitro and in early clinical studies, while no published reports evaluate rhEPO in animal models of FA. STS-E412 and STS-E424 are novel small molecule agonists of the tissue-protective, but not the erythropoietic EPO receptor. We find that rhEPO, STS-E412 and STS-E424 increase FXN expression in vitro and in vivo. RhEPO, STS-E412 and STS-E424 increase FXN by up to 2-fold in primary human cortical cells and in retinoic-acid differentiated murine P19 cells. In primary human cortical cells, the increase in FXN protein was accompanied by an increase in FXN mRNA, detectable within 4 h. RhEPO and low nanomolar concentrations of STS-E412 and STS-E424 also increase FXN in normal and FA patient-derived PBMC by 20%-40% within 24 h, an effect that was comparable to that by HDAC inhibitor 4b. In vivo, STS-E412 increased Fxn mRNA and protein in wild-type C57BL6/j mice. RhEPO, STS-E412, and STS-E424 increase FXN expression in the heart of FXN-deficient KIKO mice. In contrast, FXN expression in the brains of KIKO mice increased following treatm...Continue Reading

References

Mar 17, 2012·Pathophysiology : the Official Journal of the International Society for Pathophysiology·Lucido L PonceClaudia S Robertson

❮ Previous
Next ❯

Citations

Jul 21, 2017·Expert Review of Neurotherapeutics·Cassandra StrawserDavid R Lynch
Jul 19, 2019·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Joel M Gottesfeld
May 21, 2019·Frontiers in Neuroscience·Sylvia Boesch, Elisabetta Indelicato

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.

Related Papers

European Journal of Clinical Investigation
Brigitte SturmBarbara Scheiber-Mojdehkar
Movement Disorders : Official Journal of the Movement Disorder Society
Sylvia BoeschKaren Manicom
Journal of Neurology, Neurosurgery, and Psychiatry
Eric C DeutschD R Lynch
European Journal of Clinical Investigation
Brigitte SturmBarbara Scheiber-Mojdehkar
© 2022 Meta ULC. All rights reserved